Home › Free Stock Grades › KRYS
Krystal Biotech, Inc. (KRYS) Stock Grade
KRYS · Healthcare
A+
Market Cap
$7.1B
P/E Ratio
34.8
Revenue Growth (YoY)
+33.9%
Net Margin
52.6%
Return on Equity
16.8%
Dividend Yield
None
About Krystal Biotech, Inc.'s fundamentals
Krystal Biotech is a $7.1 billion biotechnology company experiencing strong revenue growth of 33.9% year-over-year, accompanied by an exceptionally high net profit margin of 52.6%, indicating efficient operational performance. The company trades at a P/E ratio of 34.8 and generates a return on equity of 16.8%, reflecting moderate earnings valuation relative to profitability returns. The company currently does not pay a dividend, suggesting it reinvests earnings back into operations and research and development.